Oramed Pharmaceuticals Stock Market Outlook
| ORMP Stock | USD 3.25 0.13 3.85% |
Slightly above 50% of Oramed Pharmaceuticals' retail investors are presently thinking to get in. The analysis of overall sentiment of trading Oramed Pharmaceuticals stock suggests that some investors are interested at this time. Oramed Pharmaceuticals' investing sentiment overview a quick insight into current market opportunities from investing in Oramed Pharmaceuticals. Many technical investors use Oramed Pharmaceuticals stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Comfort Level 50
Impartial
Panic | Confidence |
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use Oramed Pharmaceuticals' input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward Oramed Pharmaceuticals.
News SentimentBullish | Hype SentimentBearish | Insider SentimentAcquiring |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Oramed Pharmaceuticals is 'Strong Buy'. A buy or sell recommendation provided by Macroaxis is an automated analysis based on historical performance and your stated risk tolerance. It serves as guidance on whether to purchase or sell Oramed Pharmaceuticals within the specified time frame.
Execute Oramed Pharmaceuticals Advice
The Oramed recommendation should be used to complement the investment advice compiled from the current analysts' consensus on Oramed Pharmaceuticals. Macroaxis does not own or have any residual interests in Oramed Pharmaceuticals or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Oramed Pharmaceuticals' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Buy
Market Performance | Solid | Details | |
Volatility | Unstable | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Small | Details | |
Economic Sensitivity | Hyperactively responds to market trends | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Hold | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
For the selected time horizon Oramed Pharmaceuticals has a Risk Adjusted Performance of 0.1751, Jensen Alpha of 0.558, Total Risk Alpha of 0.3273, Sortino Ratio of 0.2404 and Treynor Ratio of 0.3598We provide trade recommendations to complement the recent expert consensus on Oramed Pharmaceuticals. Our dynamic recommendation engine exercises a multidimensional algorithm to analyze the firm's potential to grow using all technical and fundamental data available at the time. To make sure Oramed Pharmaceuticals is not overpriced, please check all Oramed Pharmaceuticals fundamentals, including its cash per share, market capitalization, and the relationship between the price to sales and cash flow from operations . Given that Oramed Pharmaceuticals has a number of shares shorted of 644.91 K, we recommend you to check out Oramed Pharmaceuticals market performance and probability of bankruptcy to ensure the company can sustain itself in the current economic cycle given your recent risk tolerance and investing horizon.
Oramed Pharmaceuticals Trading Alerts and Improvement Suggestions
| Oramed Pharmaceuticals appears to be risky and price may revert if volatility continues | |
| Net Loss for the year was (19.06 M) with profit before overhead, payroll, taxes, and interest of 13 K. | |
| Oramed Pharmaceuticals currently holds about 133.91 M in cash with (8.41 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.45, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Oramed Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Roughly 15.0% of the company outstanding shares are owned by corporate insiders | |
| On 26th of January 2026 Oramed Pharmaceuticals paid $ 0.25 per share dividend to its current shareholders | |
| Latest headline from thelincolnianonline.com: Coya Therapeutics Buy Rating Reiterated at HC Wainwright |
Oramed Pharmaceuticals Returns Distribution Density
The distribution of Oramed Pharmaceuticals' historical returns is an attempt to chart the uncertainty of Oramed Pharmaceuticals' future price movements. The chart of the probability distribution of Oramed Pharmaceuticals daily returns describes the distribution of returns around its average expected value. We use Oramed Pharmaceuticals price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Oramed Pharmaceuticals returns is essential to provide solid investment analysis for Oramed Pharmaceuticals.
| Mean Return | 0.76 | Value At Risk | -3.85 | Potential Upside | 6.98 | Standard Deviation | 3.62 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Oramed Pharmaceuticals historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Oramed Stock Institutional Investors
The Oramed Pharmaceuticals' institutional investors refer to entities that pool money to purchase Oramed Pharmaceuticals' securities or originate loans. These institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds.
| Shares | Connor Clark & Lunn Inv Mgmt Ltd | 2025-06-30 | 60.4 K | Susquehanna International Group, Llp | 2025-06-30 | 48.4 K | Royal Bank Of Canada | 2025-06-30 | 47.6 K | Squarepoint Ops Llc | 2025-06-30 | 46.1 K | Rbf Llc | 2025-06-30 | 42.9 K | Jane Street Group Llc | 2025-06-30 | 42.4 K | Morgan Stanley - Brokerage Accounts | 2025-06-30 | 32.1 K | Geode Capital Management, Llc | 2025-06-30 | 24.3 K | Pnc Financial Services Group Inc | 2025-06-30 | 23.2 K | Bml Capital Management Llc | 2025-06-30 | 3.1 M | Murchinson Ltd. | 2025-06-30 | 1.8 M |
Oramed Pharmaceuticals Cash Flow Accounts
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Change In Cash | 57.9M | (36.8M) | (31.4M) | 45.4M | 52.2M | 54.8M | |
| Free Cash Flow | (21.6M) | (29.2M) | (10.5M) | (8.4M) | (7.6M) | (8.0M) | |
| Capital Expenditures | 375.0K | 496.0K | 254.0K | 18.0K | 20.7K | 19.7K | |
| Net Income | (22.2M) | (36.6M) | 5.5M | (19.1M) | (17.2M) | (16.3M) | |
| Other Non Cash Items | 2.3M | 8.7M | (13.3M) | 7.3M | 8.3M | 8.8M | |
| End Period Cash Flow | 77.2M | 40.5M | 9.1M | 54.4M | 62.6M | 65.7M | |
| Depreciation | 77K | 58K | 196K | 193K | 222.0K | 233.0K | |
| Investments | (23.8M) | 30.2M | (73.0M) | 105.8M | 121.7M | 127.8M |
Oramed Pharmaceuticals Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Oramed Pharmaceuticals or Pharmaceuticals sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Oramed Pharmaceuticals' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Oramed stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 0.56 | |
β | Beta against Dow Jones | 2.09 | |
σ | Overall volatility | 3.64 | |
Ir | Information ratio | 0.18 |
Oramed Pharmaceuticals Volatility Alert
Oramed Pharmaceuticals currently demonstrates below-average downside deviation. It has Information Ratio of 0.18 and Jensen Alpha of 0.56. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Oramed Pharmaceuticals' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Oramed Pharmaceuticals' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Oramed Pharmaceuticals Fundamentals Vs Peers
Comparing Oramed Pharmaceuticals' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Oramed Pharmaceuticals' direct or indirect competition across all of the common fundamentals between Oramed Pharmaceuticals and the related equities. This way, we can detect undervalued stocks with similar characteristics as Oramed Pharmaceuticals or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Oramed Pharmaceuticals' fundamental indicators could also be used in its relative valuation, which is a method of valuing Oramed Pharmaceuticals by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Oramed Pharmaceuticals to competition |
| Fundamentals | Oramed Pharmaceuticals | Peer Average |
| Return On Equity | 0.24 | -0.31 |
| Return On Asset | -0.0422 | -0.14 |
| Profit Margin | 21.93 % | (1.27) % |
| Operating Margin | (6.51) % | (5.51) % |
| Current Valuation | 705.3 K | 16.62 B |
| Shares Outstanding | 39.8 M | 571.82 M |
| Shares Owned By Insiders | 14.60 % | 10.09 % |
| Shares Owned By Institutions | 23.25 % | 39.21 % |
| Number Of Shares Shorted | 644.91 K | 4.71 M |
| Price To Earning | (11.22) X | 28.72 X |
| Price To Book | 0.66 X | 9.51 X |
| Price To Sales | 64.75 X | 11.42 X |
| Gross Profit | 13 K | 27.38 B |
| EBITDA | (14.87 M) | 3.9 B |
| Net Income | (19.06 M) | 570.98 M |
| Cash And Equivalents | 133.91 M | 2.7 B |
| Cash Per Share | 3.45 X | 5.01 X |
| Total Debt | 372 K | 5.32 B |
| Debt To Equity | 0.01 % | 48.70 % |
| Current Ratio | 21.01 X | 2.16 X |
| Book Value Per Share | 4.98 X | 1.93 K |
| Cash Flow From Operations | (8.41 M) | 971.22 M |
| Short Ratio | 2.08 X | 4.00 X |
| Earnings Per Share | 0.96 X | 3.12 X |
| Target Price | 3.25 | |
| Beta | 1.31 | -0.15 |
| Market Capitalization | 129.51 M | 19.03 B |
| Total Asset | 155.28 M | 29.47 B |
| Retained Earnings | (176.62 M) | 9.33 B |
| Working Capital | 137.54 M | 1.48 B |
| Current Asset | 31 M | 9.34 B |
| Current Liabilities | 4 M | 7.9 B |
| Annual Yield | 0.07 % |
Note: Disposition of 109000 shares by Kidron Nadav of Oramed Pharmaceuticals subject to Rule 16b-3 [view details]
Oramed Pharmaceuticals Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Oramed . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
| Accumulation Distribution | 5534.87 | |||
| Daily Balance Of Power | (0.68) | |||
| Rate Of Daily Change | 0.96 | |||
| Day Median Price | 3.31 | |||
| Day Typical Price | 3.29 | |||
| Price Action Indicator | (0.12) | |||
| Period Momentum Indicator | (0.13) |
About Oramed Pharmaceuticals Buy or Sell Advice
When is the right time to buy or sell Oramed Pharmaceuticals? Buying financial instruments such as Oramed Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Oramed Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Silver Thematic Idea Now
Silver
Companies involved in mining, production, and distribution of silver and silver goods. The Silver theme has 48 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Silver Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Oramed Stock Analysis
When running Oramed Pharmaceuticals' price analysis, check to measure Oramed Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oramed Pharmaceuticals is operating at the current time. Most of Oramed Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Oramed Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oramed Pharmaceuticals' price. Additionally, you may evaluate how the addition of Oramed Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.